{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:23:40Z","timestamp":1783023820394,"version":"3.54.6"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004388","name":"Teva Branded Pharmeceutical Products R&amp;D Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jpsychires.2026.05.017","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:34:32Z","timestamp":1778654072000},"page":"112-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world patient characteristics, treatment patterns, and healthcare resource utilization and costs of tardive dyskinesia in Germany"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayla","family":"Chaijale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4338-0222","authenticated-orcid":false,"given":"Krzysztof","family":"Duma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6840-4066","authenticated-orcid":false,"given":"Joachim","family":"Hipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice T.","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2026.05.017_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2022"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib2","first-page":"106","article-title":"Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiol","volume":"25","author":"Andersohn","year":"2016","journal-title":"Drug Saf."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib5","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.4088\/JCP.v69n1008","article-title":"Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study","volume":"69","author":"Ascher-Svanum","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib6","first-page":"154","article-title":"An experimental study to assess the professional and social consequences of tardive dyskinesia. Clin. Psychopharmacol","volume":"20","author":"Ayyagari","year":"2022","journal-title":"Neuroscience"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/JCP.0000000000001597","article-title":"The clinical and economic burden of tardive dyskinesia in Israel: real-world data analysis","volume":"42","author":"Barer","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","article-title":"Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm","volume":"389","author":"Bhidayasiri","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib9","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","volume":"78","author":"Carbon","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/wps.20579","article-title":"Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis","volume":"17","author":"Carbon","year":"2018","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib11","first-page":"4","article-title":"A new era in the diagnosis and treatment of tardive dyskinesia","author":"Caroff","year":"2022","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12888-018-1889-2","article-title":"Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia","volume":"18","author":"Caroff","year":"2018","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jns.2018.02.015","article-title":"Historical perspectives on tardive dyskinesia","volume":"389","author":"Caroff","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/JCP.0000000000001201","article-title":"RE-KINECT: a prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings","volume":"40","author":"Caroff","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib16","article-title":"Healthcare utilization and costs for patients with tardive dyskinesia","author":"Carroll","year":"2017","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib15","first-page":"810","article-title":"Health care resource utilization and costs for patients with tardive dyskinesia","volume":"25","author":"Carroll","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib17","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.TV18059AH3C","article-title":"Revisiting tardive dyskinesia: focusing on the basics of identification and treatment","volume":"81","author":"Citrome","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr. Opin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1176\/appi.focus.20200038","article-title":"Tardive dyskinesia: spotlight on current approaches to treatment","volume":"19","author":"Debrey","year":"2021","journal-title":"Focus"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib21","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie; Psychosomatik und Nervenheilkunde e. V. (DGPPN), 2019. S3-Leitlinie Schizophrenie. AWMF-Register Nr. 038-009."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib22","article-title":"Clinical practice guidelines for the treatment of tardive dyskinesia in Europe: a descriptive review","author":"Edwards","year":"2024","journal-title":"37th European College Neuropsychopharmacol Congress"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib23","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s10488-020-01077-4","article-title":"Differential effect of community rehabilitation reform on hospitalizations of patients with chronic psychotic disorders with and without substance use disorder, Israel, 1991-2016","volume":"48","author":"Florentin","year":"2021","journal-title":"Adm. Pol. Ment. Health"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1186\/s12888-023-05132-w","article-title":"Patterns of psychiatric hospitalizations of Arab and Jewish adults with chronic psychotic disorders, before and after national mental health reforms, Israel, 1991-2016","volume":"23","author":"Florentin","year":"2023","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib25","series-title":"Kennzahlen und Faustformeln","article-title":"Kennzahlen der Gesetzlichen Krankenversicherung 2011 bis 2022","author":"f\u00fcr Gesundheit","year":"2023"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/s12888-025-06780-w","article-title":"Identifying the diagnostic gap of tardive dyskinesia: an analysis of semi-structured electronic health record data","volume":"25","author":"Griffiths","year":"2025","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1017\/S109285292000200X","article-title":"Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice","volume":"27","author":"Hauser","year":"2022","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib28","author":"Hexal"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib29","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1080\/13696998.2018.1500370","article-title":"Understanding healthcare burden and treatment patterns among young adults with schizophrenia","volume":"21","author":"Huang","year":"2018","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib30","doi-asserted-by":"crossref","first-page":"22cs14563","DOI":"10.4088\/JCP.22cs14563","article-title":"Impact-Tardive Dyskinesia (Impact-TD) Scale: a clinical tool to assess the impact of tardive dyskinesia","volume":"84","author":"Jackson","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s41687-023-00658-9","article-title":"Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States","volume":"7","author":"Jain","year":"2023","journal-title":"J. Patient-Rep. Outcomes"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib33","doi-asserted-by":"crossref","first-page":"22m14694","DOI":"10.4088\/JCP.22m14694","article-title":"Impact of tardive dyskinesia on physical, psychological, social, and professional domains of patient lives: a survey of patients in the United States","volume":"84","author":"Jain","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib31","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.nu17034ah1c","article-title":"Tardive dyskinesia: recognition, patient Assessment, and differential diagnosis","volume":"79","author":"Jain","year":"2018","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib34","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib35","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/jep.12072","article-title":"Using balance statistics to determine the optimal number of controls in matching studies","volume":"19","author":"Linden","year":"2013","journal-title":"J. Eval. Clin. Pract."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216044","article-title":"Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States","volume":"14","author":"Loughlin","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.puhe.2022.02.013","article-title":"Sampling strategy, characteristics and representativeness of the InGef research database","volume":"206","author":"Ludwig","year":"2022","journal-title":"Public Health"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib38","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/03007995.2019.1569871","article-title":"The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders","volume":"35","author":"McEvoy","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib39","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10597-013-9638-y","article-title":"Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with Medicare coverage","volume":"49","author":"Offord","year":"2013","journal-title":"Community Ment. Health J."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2019.e01745","article-title":"Analysis of risk factors and outcomes in psychiatric inpatients with tardive dyskinesia: a nationwide case-control study","volume":"5","author":"Patel","year":"2019","journal-title":"Heliyon"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib41","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12883-019-1385-4","article-title":"Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis","volume":"19","author":"Patterson-Lomba","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib42","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/0706743719828968","article-title":"Treatment recommendations for tardive dyskinesia","volume":"64","author":"Ricciardi","year":"2019","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib43","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1097\/MLR.0b013e31819c95aa","article-title":"Administrative and claims records as sources of health care cost data","volume":"47","author":"Riley","year":"2009","journal-title":"Med. Care"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4732","article-title":"Comparison of clinical characteristics between clinical trial participants and nonparticipants using electronic health record data","volume":"4","author":"Rogers","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib45","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S2215-0366(20)30264-9","article-title":"Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis","volume":"7","author":"Rubio","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib46","first-page":"59","article-title":"Drug-induced tardive dyskinesia \u2013 expert group recommendations: 2024 update","volume":"20","author":"Slawek","year":"2024","journal-title":"Pol. Przegl\u0105d Neurol."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib47","article-title":"Patient perspective on barriers to diagnosis and treatment of tardive dyskinesia: results from a cross-sectional survey","author":"Solis","year":"2024","journal-title":"Ann. Psych. Congress"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib49","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41380-024-02733-z","article-title":"Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis","volume":"30","author":"Solmi","year":"2025","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2018.02.012","article-title":"Clinical risk factors for the development of tardive dyskinesia","volume":"389","author":"Solmi","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1456363","article-title":"Institutional influence on length of stay in German forensic hospitals: a multilevel analysis of patients with schizophrenia spectrum disorders","volume":"15","author":"Sturner","year":"2024","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/20451253221117313","article-title":"Pathophysiology, prognosis and treatment of tardive dyskinesia","volume":"12","author":"Takeuchi","year":"2022","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib53","series-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"Taylor","year":"2021"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib54","article-title":"An update on tardive dyskinesia: from phenomenology to treatment","volume":"3","author":"Waln","year":"2013","journal-title":"Tremor Other Hyperkinet. Mov. (N Y)"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40120-018-0105-0","article-title":"Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management","volume":"7","author":"Ward","year":"2018","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib56","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1080\/10826084.2021.1949615","article-title":"Psychiatric hospitalization and length of stay differences in cannabis users and non-users with a primary discharge diagnosis of schizophrenia or schizoaffective disorder","volume":"56","author":"Williams","year":"2021","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.jpsychires.2026.05.017_bib57","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11126-015-9412-0","article-title":"The cost of inpatient care of schizophrenia and treatment schedules used in German academic center: Kiel","volume":"87","author":"Zaprutko","year":"2016","journal-title":"Psychiatr. Q."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib58","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s40261-021-01060-3","article-title":"The impact of antipsychotic dose reduction on clinical outcomes and health care resource use among medicare patients with schizophrenia","volume":"41","author":"Zichlin","year":"2021","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.jpsychires.2026.05.017_bib59","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5334\/tohm.199","article-title":"Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic","volume":"4","author":"Zutshi","year":"2014","journal-title":"Tremor Other Hyperkinet. Mov. (N Y)"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395626002682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395626002682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:50:32Z","timestamp":1783021832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395626002682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":56,"alternative-id":["S0022395626002682"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2026.05.017","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world patient characteristics, treatment patterns, and healthcare resource utilization and costs of tardive dyskinesia in Germany","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2026.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}